Compare Carnival Corp (CCL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carnival Corp vs BIO-TECHNE Corp — how do they compare? Carnival Corp trades at $27.66 (market cap $39.71B), while BIO-TECHNE Corp trades at $72.05 (market cap $11.24B). The key difference: Carnival Corp is far larger — about 3.5× BIO-TECHNE Corp's market cap, and Carnival Corp pays the higher dividend (1.55%). Which is the better fit depends on your goals.
| CCL | TECH | |
|---|---|---|
Market Cap | $39.71B | $11.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $33.99 | $72.29 |
52-Week Low | $23.89 | $43.31 |
Enterprise Value | $63.63B | $11.32B |
Dividend Yield | 1.55% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carnival Corporation (CCL) trades at $28.99, up 0.69% today, with a bullish technical signal from moving averages and strong support at $28. The stock shows robust fundamentals, with revenue growing to $26.62B in 2025 and net income at $2.76B, while recent quarters have beaten EPS estimates. Analysts maintain a buy consensus with a $35.18 price target, and positive news highlights fleet expansion and sustainability initiatives.
The outlook for CCL is positive, driven by record travel demand, cost control, and debt reduction, offering potential upside to the consensus target. Risks include fuel price volatility, economic sensitivity, and high leverage, though improved cash flow and dividend reinstatement support investor confidence.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carnival Corp
Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.
Read more on CCL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
